Research Brief 190
Superfund Research Program
Determining Susceptibility to Environmentally-induced Neurotoxicity
View Research Brief as PDF(393KB)
For over 20 years, Dr. Clement Furlong's research group at the University of Washington has focused on the role of the paraoxonase 1 gene (PON1) in metabolism of organophosphate (OP) pesticides. With funding from NIEHS and the Superfund Research Program, this group has made significant contributions:
- Isolated and cloned human and rabbit PON1, and identified a polymorphism at position 192 in the coding sequence of the gene that plays a critical role in PON1 catalytic efficiency.
- Developed the concept of "PON1 status". This assay uses the characterization of genotype (PON1R192 vs. PON1Q192 isoform) and the phenotype (level of PON1 in the plasma) to determine how rapidly an individual will metabolize a toxicant. "PON1 status" is used by laboratories around the world to investigate risk factors for disease or exposures.
- Developed an animal model to investigate the importance of PON1 variability in determining sensitivity to OP exposures. This study identified the potential for the use of PON1 to protect against the acute toxicity of specific OP exposures.
- Showed that PON1 status is important in modulating the effects of exposures to mixtures of OP pesticides.
- Conducted studies of PON1 genetic variability in Parkinson's disease patients, yielding a new approach for identifying disease risk in men. Identifying individuals at risk may allow for preventative therapy prior to symptom onset.
In current studies, Dr. Furlong is working to identify biomarkers of exposure and susceptibility to OP pesticides and related compounds.
The Furlong research group has successfully identified biomarkers for two quite different OP toxicants with very different exposure scenarios, and has optimized rapid protein target enrichment and mass spectrometric analytical protocols for each.
PON1 status as a biomarker of susceptibility to OP pesticides: Plasma cholinesterase (BChE) inhibition is a well-established biomarker of early OP-related biological effects. In collaboration with the Washington State Department of Labor and Industry, Dr. Furlong's group examined the relationship between BChE inhibition and PON1 status following pesticide handlers' exposure to OP pesticides. This large study, with extensive documentation of individual exposures, established that low PON1 status (PON1Q192 isoform and low levels of PON1 in the plasma) is a determinant of levels of BChE inhibition among OP-exposed agriculture workers. This finding suggests that PON1 status should be considered as a biomarker of susceptibility to OP-related effects and that regulatory risk assessors should consider differences in PON1-related sensitivity to OP insecticides when characterizing inter-individual variability in risk related to OP exposure.
Biomarkers of exposure to TCP: Air crew members have reported neurological symptoms such as dizziness, nausea, blurred vision, tremors and short-term memory issues. These symptoms, "aerotoxic syndrome", are suspected to be related to incidents of cabin air contamination with engine fumes containing tricresyl phosphate (TCP), a common additive in engine lubricants and hydraulic fluids. Incident reports suggest that some individuals are significantly more sensitive than others to the neurotoxic exposures, and Dr. Furlong applied his expertise with OP-related neurotoxicity to search for modified proteins as biomarkers of exposure to TCP. His research group used mass spectroscopy to examine adducts formed on BChE following reaction with CBDP (TCP is activated to CBDP in vivo). They focused on regions of BChE known to react with OP pesticides and, using samples of CBDP-spiked plasma, identified phosphoserine adducts on Ser198 that can serve as biomarkers of exposure. This diagnostic tool will contribute greatly to epidemiologic studies on aerotoxic syndrome as well as pesticide exposures among agricultural workers.
Significance: Dr. Furlong's research is contributing to our understanding of the genetic and developmental variability in sensitivity to the toxicity of OP pesticides and reducing the uncertainty in risk assessment. He actively interacts with environmental and health agencies at the state, federal, and international level to communicate his findings to support policy decisions and programs that have direct impacts on public health. Dr. Furlong's work was considered in EPA's decisions to restrict use of chlorpyrifos and diazanon, and the State of Washington has incorporated his findings on genetic and developmental variability in resistance to OP pesticides into its pesticide training program.
The biomarker protocols that his research group developed are useful not only for OP pesticides, but to evaluate exposures to nerve agents (e.g., Sarin) and to TCP exposures in aircraft. Dr. Furlong's work to develop assays for Parkinson's disease may be useful for early diagnosis and for monitoring the efficacy of therapeutic protocols. The PON1 status analysis has also proven useful in identifying low PON1 status as a risk for carotid artery disease.
For More Information Contact:
Clement E Furlong
University of Washington
Department of Medicine and Genome Sciences
Division of Medical Genetics
Seattle, WA 98195
To learn more about this research, please refer to the following sources:
- Hofmann JN, Keifer M, De Roos AJ, Fenske RA, Furlong CE, van Belle G, Checkoway H. 2010. Occupational determinants of serum cholinesterase inhibition among organophosphate-exposed agricultural pesticide handlers in Washington State. Occup Environ Med 67(6):375-386. doi:10.1136/oem.2009.046391 PMID:19819864 PMCID:PMC2908529
- Schopfer L, Furlong CE, Lockridge O. 2010. Development of diagnostics in the search for an explanation of aerotoxic syndrome. Anal Biochem 404(1):64-74. doi:10.1016/j.ab.2010.04.032 PMID:20447373 PMCID:PMC2900449
- Ticozzi N, LeClerc AL, Keagle PJ, Glass JD, Wills AM, van Blitterswijk M, Bosco DA, Rodriguez-Leyva I, Gellera C, Ratti A, Taroni F, McKenna-Yasek D, Sapp PC, Silvani V, Furlong CE, Brown RH, Landers JE. 2010. Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann Neurol 68(1):102-107. doi:10.1002/ana.21993 PMID:20582942 PMCID:PMC2945725
- Hofmann JN, Keifer M, Furlong CE, De Roos AJ, Farin FM, Fenske RA, van Belle G, Checkoway H. 2009. Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers. Environ Health Perspect 117:1402-1408. PMID:19750105
- Jansen KL, Cole TB, Park SS, Furlong CE, Costa LG. 2009. Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicol Appl Pharmacol 236(2):142-153. doi:10.1016/j.taap.2009.02.001 PMID:19371602 PMCID:PMC2717945
- Richter RJ, Jarvik GP, Furlong CE. 2008. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet 1(2):147-152. doi:10.1161/CIRCGENETICS.108.811638 PMID:20031556 PMCID:PMC3035628
- Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE. 2008. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci U S A 105(35):12780-12784. doi:10.1073/pnas.0805865105 PMID:18711144 PMCID:PMC2529096
To receive monthly mailings of the Research Briefs, send your email address to firstname.lastname@example.org.